Pharma

Your Article Summary

See Latest Articles

European Committee for Human Medicinal Products (CHMP) Issues Positive Opinion for Once-Daily PREZISTA (Darunavir) as Part of Combination Therapy for Treatment-Naive Adults With HIV-1
Corporate News Releases - The Healthcare Sales & Marketing Network, 12/02/08

The Committee for Human Medicinal Products (CHMP) has issued a positive opinion recommending approval for once-daily dosing of 800 mg PREZISTA (darunavir) with low-dose ritonavir as part of combination therapy in treatment-naive adults (those who have never taken HIV medication before). Darunavir, a protease inhibitor, was developed by Tibotec Pharmaceuticals, and Tibotec, a division of Janssen-Cilag, is the organisation responsible for marketing the brand in Europe.

Today in Research & Development...keeping you current

Receive free subspecialty "5-minute updates" via email

AstraZeneca and the University of Virginia sign strategic research collaboration to develop novel treatments for cardiovascular disease
AstraZeneca, 12/16/09

Sanofi Pasteur expands study of vaccine against Clostridium difficile into the U.S.
Sanofi-aventis, 12/16/09

Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
Amylin Pharmaceuticals, 12/16/09

 See all of Research & Development